Hartmut Erhlich

Prof. Hartmut Ehrlich, M.D., is Momentous’ Chief Business Officer, a physician-scientist (h-index: 45) and global leader/entrepreneur with almost 40 years in the bio-pharmaceutical industry, most recently as CEO of Abivax (2013-2023) in Paris, France. Hartmut built Abivax (Nasdaq - ABVX) from scratch and drove the company’s lead compound obefazimod, a first-in-class oral anti-inflammatory small molecule drug candidate, from non-clinical testing into global, pivotal phase 3 development for ulcerative colitis, as well as into successful proof of concept studies for Crohn’s disease and rheumatoid arthritis. In parallel, he led Abivax’ IPO on Euronext Paris and subsequent capital market transactions as well as less dilutive funding initiatives totalling > 400 M EUR, and brought the market cap of the company to > 600 M EUR. When he stepped down as CEO of Abivax in May 2023, the market cap of Abivax was 635 M EUR and thus the highest of all Biotech companies in France.

Before that, Hartmut worked almost 20 years with Baxter BioScience, most notably as Head of Global R&D and Medical Affairs from 2006-2013. He successfully built and advanced BioScience's R&D portfolio with around 50 programs in preclinical and clinical development, and drove the successful regulatory approval of key biologics in the areas Hemophilia, Thrombosis, Immunology, Neurology, Oncology, BioSurgery and Vaccines. He also served as Baxter’s principal investigator on a grant from US DHHS, which from 2006 to 2013 paid USD 242 M for the development of cell-culture derived seasonal and pandemic influenza vaccines. In July 2014 (9 months after his departure), Baxter’s marketed vaccines were acquired by Pfizer for 635 M USD. In January 2016 (just over 2 years after his departure), Baxalta (i.e. the new name of Baxter BioScience after its US IPO) was sold to Shire for 32 B USD

Snippet

Previously Chief Executive Officer of Abivax (Nasdaq – ABVX) a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.